Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 29, 2025
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
GlobeNewswire
·
April 29, 2025
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., …
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 29, 2025
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a. …
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 29, 2025
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on …
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
GlobeNewswire
·
April 29, 2025
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a …
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
GlobeNewswire
·
April 29, 2025
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …
ProDentim Reviews (ALERT): I TRIED IT, Tracked It, and Exposed the Good, Bad & Unexpected
GlobeNewswire
·
April 29, 2025
Tallmadge, Ohio, April 29, 2025 (GLOBE NEWSWIRE) -- ProDentim is rated 5 stars by over 95,000 satisfied customers. It combines 3.5 billion CFUs of powerful probiotics, including Lactobacillus Paracasei, B.lactis BL-04®, and Lactobacillus Reuteri, along …
Britisches Unternehmen Stablepharma Ltd. beginnt mit klinischen Studien der Phase I für den weltweit ersten ohne Kühlung auskommenden Tetanus- und Diphtherie-Impfstoff
GlobeNewswire
·
April 29, 2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Nach der MHRA-Zulassung hat Stablepharma Ltd eine klinische Studie der Phase I mit seinem Hauptkandidaten, dem kühlschrankfreien Tetanus- und Diphtherieimpfstoff SPVX02, begonnen. Die klinische Phase-I-Studie am …
L’entreprise de biotechnologie britannique Stablepharma Ltd. lance en première mondiale un essai de Phase I ciblé sur un vaccin thermostable contre le tétanos et la diphtérie
GlobeNewswire
·
April 29, 2025
LONDRES, 29 avr. 2025 (GLOBE NEWSWIRE) -- Après avoir obtenu l’autorisation de la MHRA, l’autorité britannique de réglementation du marché des dispositifs médicaux, Stablepharma Ltd. entre en essai clinique de Phase I pour son principal candidat, SPVX02, …
Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism …
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
GlobeNewswire
·
April 29, 2025
Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The financing will enable Nova Anchora to advance its lead …
deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection
GlobeNewswire
·
April 29, 2025
deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection Round co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners Barcelona, Spain – 29 …
Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung
GlobeNewswire
·
April 29, 2025
Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am 20. Mai 2025 um 10:00 Uhr MESZ im Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Schweiz, …
Santhera Publishes Agenda for its Annual General Meeting
GlobeNewswire
·
April 29, 2025
Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, …
Gesamtjahresergebnisse für das am 31. Dezember 2024 endende Jahr
GlobeNewswire
·
April 29, 2025
Ein Jahr des Wandels nach der erfolgreichen Einführung von AGAMREE® Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute die Ergebnisse für das am 31. Dezember 2024 abgeschlossene Geschäftsjahr bekannt. Dario Eklund, CEO von …
Santhera Full Year Results for the Year Ended 31 December 2024
GlobeNewswire
·
April 29, 2025
Transformational year following the successful launch of AGAMREE® Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2024. Dario Eklund, CEO of Santhera said: “ …
Lumineye Introduces Sublingual Nano-Drop Formula to Help Support Normal Eye Comfort and Clarity
GlobeNewswire
·
April 29, 2025
Sheridan, Wyoming, USA, April 29, 2025 (GLOBE NEWSWIRE) -- Lumineye, a pioneering company in the health and wellness sector, today announced the launch of its new product: The Lumineye Nanodrop. This advanced dietary supplement utilizes a novel sublingual …